|
4. Significant Strategic Drug Development Collaborations (Details Narrative) (USD $)
|
12 Months Ended | |
|---|---|---|
|
Dec. 31, 2014
|
Dec. 31, 2013
|
|
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||
| Shares issued for equity investment, value | $ 10,811,196us-gaap_StockIssuedDuringPeriodValueNewIssues | |
| Revenue recognized | 0us-gaap_Revenues | 1,000,000us-gaap_Revenues |
| Baxter Healthcare | ||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||
| Shares issued for equity investment, shares |
10,695,187us-gaap_StockIssuedDuringPeriodSharesNewIssues / us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis = xbio_BaxterMember |
|
| Shares issued for equity investment, value |
10,000,000us-gaap_StockIssuedDuringPeriodValueNewIssues / us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis = xbio_BaxterMember |
|
| Revenue recognized |
1,000,000us-gaap_Revenues / us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis = xbio_BaxterMember |
|
| Percent ownership in Xenetic |
8.70%us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners / us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis = xbio_BaxterMember |
1.80%us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners / us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis = xbio_BaxterMember |
| SynBio LLC | ||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||
| Revenue recognized |
0us-gaap_Revenues / us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis = xbio_SynBioMember |
|
| Warrant granted to purchase common stock |
6,745,000us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight / us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis = xbio_SynBioMember |
|
| Serum Institute of India Ltd | ||
| Research and Development Arrangement, Contract to Perform for Others [Line Items] | ||
| Revenue recognized |
$ 0us-gaap_Revenues / us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis = xbio_SerumInstituteMember |
|
| Percent ownership in Xenetic |
9.20%us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners / us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis = xbio_SerumInstituteMember |
10.60%us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners / us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis = xbio_SerumInstituteMember |
| Warrant granted to purchase common stock |
3,200,000us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight / us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis = xbio_SerumInstituteMember |
|
| X | ||||||||||
|
- Definition
Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. No definition available.
|
| X | ||||||||||
|
- Definition
The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity. No definition available.
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Number of new stock issued during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|